preloader icon



Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio

AKRO stock and ETNB stock crashed Tuesday after Akero's treatment for the liver disease, NASH, fell short in a midstage study.
Click Here To Get Funded!